|2.||Melanoma (Melanoma, Malignant)
|3.||Neoplasm Metastasis (Metastasis)
|5.||Sarcoma (Soft Tissue Sarcoma)
|1.||Akihisa, Toshihiro: 20 articles (04/2015 - 09/2006)|
|2.||Kim, Youngsoo: 18 articles (06/2013 - 12/2004)|
|3.||Matsuda, Hisashi: 13 articles (07/2014 - 12/2003)|
|4.||Yoshikawa, Masayuki: 13 articles (07/2014 - 12/2003)|
|5.||Kondo, Ryuichiro: 12 articles (07/2015 - 07/2006)|
|6.||Zhang, Jie: 12 articles (04/2015 - 02/2005)|
|7.||Jung, Sang-Hun: 12 articles (06/2013 - 02/2010)|
|8.||Ohguchi, Kenji: 12 articles (10/2010 - 03/2003)|
|9.||Nozawa, Yoshinori: 12 articles (10/2010 - 03/2003)|
|10.||Nakashima, Souichi: 11 articles (07/2014 - 08/2009)|
09/01/2002 - "To improve the therapeutic efficacy of fusion protein C215Fab-SEA we investigated in this study the antitumor responses elicited by combination of C215Fab-SEA and adenovirus-mediated intratumoral Lptn gene transfer in the preestablished C215 antigen expressing B16 melanoma murine model. "
02/01/2007 - "We have investigated the tumour therapeutic efficacy of homologous and heterologous prime-boost vaccine strategies against the 5T4 oncofoetal antigen, using both replication defective adenovirus expressing human 5T4 (Ad5T4), and retrovirally transduced DC lines (DCh5T4) in a subcutaneous B16 melanoma model (B16h5T4). "
05/10/1991 - "The H-2b-negative B78HI clone (derived from B16 melanoma) was transfected with the H-2Kb gene; 4 cell clones expressing membrane H-2Kb antigens and 2 control clones (transfected with pSV2neo alone) were used for studies of metastatic ability, immunogenicity, NK sensitivity and homotypic adhesion. "
10/15/1990 - "In the present study, the reactivity of 8F11 to murine B16 melanoma and its metastatic variants was examined, and the antigen recognized by 8F11 on the cell surface was characterized. "
05/01/2015 - "We engineered MCMV to express a modified B16 melanoma antigen gp100 (MCMV-gp100KGP). "
|2.||DNA (Deoxyribonucleic Acid)IBA
12/01/2008 - "Finally, we show that TA99 improves therapeutic efficacy of DNA vaccination combined with adoptive T-cell transfer in treatment of established subcutaneous B16 melanoma. "
08/01/2006 - "We have previously shown that application of xenogeneic human gp100 DNA (hgp100 DNA) is protective against mouse B16 melanoma. "
03/01/2008 - "Decreased DNA ploidy may constitute a mechanism of the reduced malignant behavior of B16 melanoma in aged mice."
02/01/2007 - "Using the human gp100 xenogeneic TAA in the murine B16 melanoma model, we show that genetic vaccination of mice by HLV plasmid DNA delivery was highly effective at breaking tolerance against the homologous murine gp100 (mgp100) TAA and induced prophylactic antitumor protection. "
05/15/2003 - "Furthermore, mice immunized with DNA constructs of hgp100 in which the hgp100(25-27) epitope was substituted with the weaker D(b)-binding epitope from mgp100 (mgp100(25-27)) or a mutated epitope unable to bind D(b) did not reject B16 melanoma. "
03/01/2013 - "In this study we examined the effect of local production of IL-2 on the growth and the immune response to B16 melanoma cells. "
01/01/2015 - "Here, B6 mice were challenged with poorly immunogenic B16 melanoma on day 0, and treated with CTLA-4 blocking antibody (100 μg/mouse) on days 3, 6, and 9, and IL-2 (100,000 units) twice daily on days 4-8, or both. "
03/01/2013 - "Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy."
02/01/2002 - "We found that OTZ, by depressing GSH levels, abrogates the in vitro growth-promoting effects of IL2 on B16 melanoma cells. "
11/01/1998 - "We have tested this agent in combination with adoptive immunotherapy using IL-2 activated natural killer (A-NK) cells in a metastatic B16 melanoma model in C57BL/6 mice. "
|4.||Monophenol Monooxygenase (Tyrosinase)IBA
10/01/2009 - "In this study, the compound was evaluated for in vitro cellular tyrosinase and melanogenesis inhibitory activities in mouse B16 melanoma cells and for in vivo skin-whitening activity in human volunteers. "
10/30/1990 - "Our studies suggest that the adhesion-mediated modulation of pigmentation in B16 melanoma correlates with differential macromolecular interactions with the 3' end of the tyrosinase gene."
08/07/2015 - "After 2 days of culture in the presence of Wnt-CM, proliferation of B16 melanoma cells was inhibited, whereas tyrosinase activity was increased. "
05/01/2015 - "Inhibition of PAK4 over several days markedly decreased the levels of CREB, MITF, and tyrosinase in both HRM-2 mice and B16 melanoma cells. "
10/01/2013 - "In addition, MHY-794 effectively inhibited SNP (NO donor)-induced melanogenesis by directly inhibiting tyrosinase and diminishing NO-mediated melanogenesis signaling in B16 melanoma cells. "
|5.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/01/1983 - "The main results were as follows: (a) long-term survival can be reached only by accepting a relatively high toxicity in each case, and (b) in the L1210 model the three-drug combination was superior to the two-drug combination, while in the B16 melanoma cyclophosphamide as a single agent offered the best results. "
02/01/2009 - "We found that combination therapy with anti-4-1BB and cyclophosphamide (CTX) produced synergistic anticancer effects in the poorly immunogenic B16 melanoma model in mice. "
06/01/2007 - "Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. "
07/01/2005 - "Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions."
01/01/2003 - "Combination therapy also promoted animetastatic effect: melanoma B16 inhibition by cyclophosphamide alone was 50% vs. 80% after cyclophosphamide plus NO-donor. "
|6.||Doxorubicin (Adriamycin)FDA LinkGeneric
10/01/1991 - "Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study."
11/01/2010 - "Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells."
10/01/2004 - "Finally, we demonstrate that doxorubicin conjugated with OHB is effectively taken up by murine melanoma B16(F10) cells in vitro and localizes in the cytoplasm. "
06/01/1998 - "However, 12b was less active than Adriamycin when tested in vivo against P388 leukaemia or the B16 melanoma tumour models."
07/01/1994 - "We examined the in vitro effects of 8-chloro-adenosine 3':5'-monophosphate (8-Cl-cAMP), a reportedly stable, potent and site-selective analogue of cAMP, on the proliferation and sensitivity to doxorubicin (DXR) of two mouse cell lines, the B16 melanoma and Friend leukaemia, both as wild-type (B16, FLC) and DXR-resistant (B16/DXR, FLC/DXR) variants. "
|7.||Interleukin-12 (IL 12)IBA
02/01/2003 - "In this study, we have examined and compared the role of NKT cells, T cells, NK cells, and other non-T non-B cells in the rejection of B16 melanoma cells after exogenous administration of IL-12. "
08/01/2012 - "A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model."
06/15/2008 - "We also showed that the anticancer effect exerted by the IL-12 MSCs is immune mediated because it is absent in immunodeficient mice, is not due to systemic IL-12 delivery, and also occurs in a B16 melanoma model. "
12/01/2000 - "We emphasize that this T helper type 1-dominant cytokine profile may generate further activated CD8(+) T cells against B16 melanoma cells, lead B16/interleukin-12 to regress, and result in the destruction of the melanocytes in hair bulbs due to cross-antigenicity between both cell types. "
07/15/1998 - "inoculated B16 melanoma for up to 2 weeks after the last injection of IL-12. "
01/01/2015 - "A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma."
07/01/2014 - "The protocol was validated in vivo on mice-bearing subcutaneous syngeneic B16 melanoma and i.v. injected with the paramagnetic liposomes. "
12/01/2003 - "A human hsp70 gene mediated by cationic liposomes was injected into a B16 melanoma nodule in C57BL/6 mice in situ. "
01/01/1985 - "Such liposomes were able to significantly reduce the pulmonary metastatic burden of mice carrying the B16 melanoma. "
05/01/2011 - "To study the antitumor effects and mechanism of cationic liposome-mediated SurvivinT34A mutants in mice with pulmonary metastases of melanoma B16. "
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/01/2015 - "Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma."
01/01/2007 - "We have previously shown GM3 to positively regulate TNF-alpha expression via a PI3K/Akt pathway in mouse melanoma B16 cells [Wang et al.: Biochem Biophys Res Commun 2007;356:438-443]. "
01/01/2007 - "GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells."
12/26/2003 - "The present findings suggest that MEK1/2 plays an important role in TNF-alpha-resistance in TNF-alpha-resistant B16 melanoma BL6 cells. "
12/26/2003 - "Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpha-resistant B16 melanoma BL6 cells."
|10.||Interferon-gamma (Interferon, gamma)IBA
07/01/2005 - "To examine the antitumor efficacy of intratumoral injection of interferon-gamma gene-modified dendritic cells (DC-IFN-gamma) in a B16 melanoma model and to investigate its related immunological mechanisms. "
08/31/1989 - "Interferon-gamma (IFN-gamma) can enhance the experimental metastatic ability of B16 melanoma. "
02/15/1988 - "Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread."
05/01/1987 - "Treatment of H-2-deficient nonmetastatic B16 melanoma cells with physiological doses of interferon gamma (IFN-gamma) reduced cellular growth in vitro but induced a shift to the lung-colonizing phenotype as assessed after intravenous injection of the treated cells. "
09/29/2006 - "Vaccination of C57BL/6 mice elicited measurable cellular responses by interferon gamma (IFN gamma) ELISpot and resulted in significantly improved protection from tumor challenge in both the EG.7-Ova and B16 melanoma models. "
02/01/1995 - "In vivo distribution studies showed that hTf(Fe)2, the Ki of which was 5.3 nM to mouse melanoma B16 cells, was eliminated from plasma biexponentially in the B16-bearing and control mice after intravenous injection at a dose of 87 mg/kg, and AUCplasma values were 29 and 39 mg.h/mL, respectively. "
05/01/1998 - "The present study was designed to evaluate the antimetastatic effects of this preparation following intravenous injection of B16 melanoma cells into mice. "
09/01/2004 - "After rest or exercise on the last day of training, syngeneic B16 melanoma cells (2 x 10(5)) were administered via intravenous injection (n = 8-11 per group). "
05/01/1998 - "Mice received intravenous injections of syngeneic B16 melanoma cells 30 min postexercise. "
09/01/1992 - "By microscopical observation and using an original method of automatic image analysis, we studied on histological sections the rate of lung colony formation after intravenous injection into the mouse of B16 melanoma cells previously cultivated in vitro as pure or mixed spheroids (B16 + 3T3 fibroblasts). "
09/01/1998 - "High doses of T alpha 1 improve anti-tumour efficacy of tnple chemo-immunotherapy against B16 melanoma. "
12/01/1977 - "This study provides a format for testing the applicability of BCG immunotherapy for experimental melanomas."
01/01/2014 - "B16 melanoma-bearing C57BL/6 mice were pretreated with CTX, followed by ACT immunotherapy using dendritic cell-induced CTLs. "
07/15/2006 - "Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma."
09/01/1998 - "Here, using mouse B16 melanoma as a model, we tested whether increasing the dose of T alpha 1 could increase the anti-tumour activity of triple combination chemo-immunotherapy. "
|3.||Heterologous Transplantation (Xenotransplantation)
12/01/1996 - "Biodistribution studies of the boronated LDL were performed in BALB/c mice bearing subcutaneous Harding-Passey melanoma xenografts. "
04/01/2011 - "Moreover, PEGylated rhArg dramatically inhibited the growth of A375 and B16 melanoma xenografts in vivo. "
02/01/2008 - "Survival rate of immunocompetent C57/BL mice was observed following intratumor injection of recombinant adenoviruses in B16 melanoma xenograft models. "
03/01/2003 - "The in vivo effects of ODN were also evaluated by models of A549 xenografts in nude mice and B16 melanoma in mice. "
09/01/2011 - "Hence, we performed vaccination of mice with GST-CXCL8, which results in a reduced incidence of syngenic B16 melanoma cell xenograft tumors. "
09/01/2005 - "In this study, we injected multiple doses of mouse B16 melanoma cells into opossums at different developmental ages (i.e., suckling young, juveniles, and adults) to determine whether immunotolerance could develop as a result of repeated "desensitizing" injections. "
04/01/2009 - "The right eyes of the mice received subretinal injections with B16 melanoma cells and the left eyes were the control. "
05/01/2005 - "Importantly, injections of the different recombinant adenoviruses all mediated protective immunity against transplanted B16 melanoma cells. "
11/28/2001 - "Most importantly, repeated intratumoral injections of Am-gamma stunted growth of established B16 melanomas in 75% of treated animals. "
09/27/1996 - "Treatment of mice carrying established lung micrometastases of the C215-transfected syngeneic B16 melanoma with 3-4 daily injections of C215Fab-SEA resulted in strong antitumor effects, while only moderate effects were seen when treatment was given every 4th day (intermittent treatment). "
07/10/2005 - "In the present study, we examined the effects of oral administration of AC-1 on protection against 2 types of murine B16 melanoma lines, major histocompatibility complex (MHC) class I-negative B16L and MHC class I gene-transfected B16K(b) cells. "
01/01/2011 - "Oral administration of immunopotentiator from Pantoea agglomerans 1 (IP-PA1) improves the survival of B16 melanoma-inoculated model mice."
02/12/2001 - "This analogue showed potent activity against B16 melanoma BL6 in vivo by oral administration."
06/15/1987 - "Finally, the repeated twice-weekly oral administrations of MTP-PE inhibited lung and lymph node metastasis in C57BL/6 mice by syngeneic B16 melanoma cells. "
01/01/1986 - "However, oral administration of the drug was not effective against B16 melanoma, colon 26 and Lewis lung carcinoma despite the fact that the doses employed for this route was higher than those employed for i.v. and i.p. "